![]() In her spare time, she volunteers as a part of the UCSF medical team supporting sporting events across the San Francisco Bay Area. She received her medical degree from Brighton and Sussex Medical School, UK with numerous accolades. Badhrinarayanan was elected as a Fellow of the Royal Society of Public Health, UK. In addition, she is the editor/reviewer of numerous high-impact journals including the British Medical Journal.įor her work and commitment towards public health, Dr. Her wide range of interests varies from AI in health care to D&I initiatives that have been embodied through her contributions to print and media as well as at conferences across the globe. To further her passion for teaching, she served as an Honorary Lecturer in Medical Education and Simulation at the University of Adelaide Medical School, Australia. Badhrinarayanan received the Edward Jenner Award from the NHS Leadership Academy. ![]() Thriving in the field of medical leadership and management, Dr. Prior to her current position, she served as a Physician with the National Health Service (NHS) in the UK, where she made significant contributions to clinical and research initiatives. In this role, she provides strategic direction for the development of new Immuno-Oncology drugs by leading cross-functional teams and conducting medical monitoring of clinical trials. Shreya Badhrinarayanan is the Medical Director for Clinical Development Oncology at Genentech, a subsidiary of Roche. Off the professional grid, Michigan is where he calls home, enjoying moments with his family and passionately supporting blood drives as a regular donor.ĭr. Beyond Takeda, Pat amassed experience across functions in companies such as Millennium Pharmaceuticals and Johnson & Johnson.Įducationally, Pat boasts an MBA with a concentration in Healthcare Leadership from Oakland University and a BS from Hillsdale College. During these years, Pat was actively involved in nine oncology product launches and contributed to several post-acquisition integrations, demonstrating adaptability and commitment. His experience at Takeda also includes a notable tenure as a National Sales Leader. As a part of the US Oncology Leadership Team, he had purview over areas like Launch Excellence, Marketing Operations, Digital Operations, and Learning and Development. At Takeda Oncology, he served as the Head of US Strategy and Operations. His journey prior to NCODA spanned a diverse 25 years in the pharmaceutical and biotech arenas. In his role, Pat oversees multiple core divisions, such as Business Development, Marketing, Communications, Public Relations, Member Events, and Partner Agreements. With a deep-seated belief in the potential of the pharmaceutical sector, Pat consistently endeavors to cultivate enriching collaborations between NCODA members and pharmaceutical partners, aiming to elevate patient outcomes via enhanced education. Patrick (Pat) Connelly serves as the Chief Development and Strategy Officer at NCODA, a pivotal role that sees him shaping the organization’s growth strategy and long-term objectives. The fund is currently open and applications are accepted on a rolling basis. The PAN Foundation’s Waldenstrom macroglobulinemia (WM) patient assistance fund provides a 12-month grant of $6,500 to pay for the deductibles, co-pays, and coinsurance costs associated with WM treatment. The PAN Foundation’s Philadelphia chromosome negative myeloproliferative neoplasms (MPN) patient assistance fund provides a 12-month grant of $8,500 to pay for the deductibles, co-pays, and coinsurance costs associated with CLL treatment. Philadelphia Chromosome Negative Myeloproliferative Neoplasms ![]() The PAN Foundation’s chronic lymphocytic leukemia (CLL) patient assistance fund provides a 12- month grant of $8,700 to pay for the deductibles, co-pays, and coinsurance costs associated with CLL treatment. Learn more about certain patient assistance funds below. The PAN Foundation is a national organization dedicated to helping federally and commercially insured people living with life-threatening, chronic, and rare diseases with the out-of-pocket costs for their prescribed medications. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |